HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
eKSP7txKFdZBqJHn